Increasing access to FDC treatments for HIV

Partnership objectives

  1. Facilitate the development and delivery of darunavir and ritonavir (DRV/rt) fixed-dose combination in resource-limited settings;
  2. Support efforts to broaden access to these formulations.

This collaboration aims to facilitate the development and delivery of a fixed-dose combination of darunavir and ritonavir (DRV/rt) for the treatment of HIV in resource-limited settings. This collaboration aims to facilitate the development and delivery of a fixed-dose combination of darunavir and ritonavir (DRV/rt) for the treatment of HIV in resource-limited settings. Copyright Johnson & Johnson

What are the health needs and challenges?

Simplifying and optimizing HIV therapy is in the best interest of people living with HIV and public health systems. Fixeed-dose combinations are important treatments for HIV as they support adherence and are preferred by public health treatment programs.

Description of partnership activities and how they address needs and challenges

Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, is collaborating with the Clinton Health Access Initiative (CHAI) to improve access to important medical solutions, and support generic manufacturers’ efforts to broaden access to these formulations.

This collaboration specifically aims to facilitate the development and delivery of a fixed-dose combination of darunavir and ritonavir (DRV/rt) for the treatment of HIV in resource-limited settings. Moreover, it intends to support the inclusion of DRV/rt as an element of second-line treatment in the World Health Organization’s recent update to its global HIV/AIDS treatment guidelines. The inclusion of DRV/rt in the guidelines will allow for enhanced access to the treatment for more patients, families and communities in need.

Partnership information

Company(ies) Johnson & Johnson

Partner(s) Clinton Health Access Initiative

Type of Partner(s) PDPs

Therapeutic Focus Infectious Diseases

Disease(s) HIV/AIDS

Program Type(s) Availability of Treatment - Differential Pricing, Availability of Treatment - Technology Transfer - Manufacturing and Entrepreneurial Know-How

Targeted Population(s) Patients in needs of treatment

Region(s) Sub-Saharan Africa

Number of Countries 48

Country(ies) Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, Chad, Comoros, Congo, Côte d'Ivoire, Democratic Republic of the Congo, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Madagascar, Malawi, Mali, Mauritania, Mauritius, Mozambique, Namibia, Niger, Nigeria, Rwanda, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, Somalia, South Africa, South Sudan, Sudan, Swaziland, Tanzania, The Gambia, Togo, Uganda, Zambia, Zimbabwe

Start Date 2016

More information Johnson & Johnson Press Release

Anticipated completion date Ongoing

« I am proud of the progress made on HIV/AIDS. We must now address the most critical disparities in prevention and global access to treatment, especially in resource-limited settings around the world. »

Paul Stoffels, Chief Scientific Officer at Johnson & Johnson and Worldwide Chairman at Janssen Pharmaceutical Companies